Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Electron microscopy of the atrium of the heart. I. Guinea pig.Exp Med Surg. 1956; 14: 99-112
- Evidence of the atrial location of receptors influencing urine flow.Circ Res. 1956; 4: 85-90
- A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats.Life Sci. 1981; 28: 89-94
- A new natriuretic peptide in porcine brain.Nature. 1988; 332: 78-81
- Natriuretic peptide family: new aspects.Curr Med Chem Cardiovasc Hematol Agents. 2005; 3: 87-98
- Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching.Endocrinology. 1993; 132: 1961-1970
- Alpha 1-adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr-1 and c-Myc expression.Endocrinology. 1996; 137: 137-143
- Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release.Circ Res. 1997; 80: 114-123
- Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction.Circulation. 1995; 92: 1558-1564
- Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.Circulation. 1991; 84: 1581-1588
- Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects.J Am Coll Cardiol. 2001; 37: 1221-1227
- Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition.J Am Coll Cardiol. 2000; 35: 796-801
- Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts.Circ Res. 2008; 102: 185-192
- Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects.J Am Coll Cardiol. 2009; 53: 884-890
- Deconvolution analysis of cardiac natriuretic peptides during acute volume overload.Hypertension. 2000; 36: 355-359
- Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.J Clin Invest. 1991; 87: 1402-1412
- Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.Am Heart J. 2006; 152: 828-834
- Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure.Circ Heart Fail. 2008; 1: 258-264
- Evidence for functional heterogeneity of circulating B-type natriuretic peptide.J Am Coll Cardiol. 2007; 49: 1071-1078
- 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation. 2013; 62: e147-e239
- Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.N Engl J Med. 2002; 347: 161-167
- The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.Am J Cardiol. 2005; 95: 948-954
- NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.Eur Heart J. 2006; 27: 330-337
- Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea.Arch Intern Med. 2008; 168: 741-748
- N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study.Circulation. 2007; 115: 3103-3110
- Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.N Engl J Med. 2004; 350: 647-654
- Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department.Am J Cardiol. 2006; 98: 800-805
- Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study.J Am Coll Cardiol. 2003; 41: 2010-2017
- The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.J Card Fail. 2005; 11: S9-S14
- Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure.Am J Cardiol. 2006; 98: 386-390
- Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care.Eur Heart J. 2010; 31: 1881-1889
- Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels.Jpn Heart J. 2000; 41: 205-214
- Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea.Arch Intern Med. 2007; 167: 400-407
- How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review.BMJ. 2005; 330: 625
- Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.J Am Coll Cardiol. 2007; 49: 1943-1950
- Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department.Arch Intern Med. 2006; 166: 315-320
- N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.Circulation. 2004; 110: 2168-2174
- Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).Circulation. 2003; 107: 1278-1283
- Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.Clin Chem. 2006; 52: 1528-1538
- Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial).J Am Coll Cardiol. 2008; 52: 997-1003
- Biomarkers and diagnostics in heart failure.Biochim Biophys Acta. 2013; 1832: 2442-2450
- Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.Lancet. 2000; 355: 1126-1130
- Biomarkers in the management of heart failure.Curr Treat Options Cardiovasc Med. 2010; 12: 519-531
- Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials.Am Heart J. 2009; 158: 422-430
- B-type natriuretic peptide-guided heart failure therapy: a meta-analysis.Arch Intern Med. 2010; 170: 507-514
- Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.J Am Coll Cardiol. 2011; 58: 1881-1889
- Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.J Am Coll Cardiol. 2010; 55: 2062-2076
- Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.Eur Heart J. 2012; 33: 2197-2205
- The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial.Eur J Heart Fail. 2010; 12: 338-347
- Third universal definition of myocardial infarction.Circulation. 2012; 126: 2020-2035
- Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction.Circulation. 1993; 88: 82-91
- Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction.Int J Cardiol. 1999; 69: 5-14
- Increased plasma levels of B-type natriuretic peptide in patients with unstable angina.Am Heart J. 1996; 132: 101-107
- Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the “Rule out myocardial infarction using computer assisted Tomography” (ROMICAT) trial.Am Heart J. 2012; 163: 972-979.e1
- A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department.Am Heart J. 2011; 162: 276-282.e1
- N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation.J Am Coll Cardiol. 2002; 40: 437-445
- N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.Circulation. 2004; 110: 3206-3212
- Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during in stability in coronary artery disease (FRISC)-II substudy.J Am Coll Cardiol. 2005; 45: 533-541
- N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease.J Am Coll Cardiol. 2003; 42: 1909-1916
Article info
Publication history
Published online: January 16, 2014
Footnotes
Funding Sources: Dr H.K. Gaggin is supported in part by the Ruth and James Clark Fund for Cardiac Research Innovation, and Dr J.L. Januzzi is supported in part by the Roman W. DeSanctis Clinical Scholar Endowment.
Disclosures: Dr J.L. Januzzi reports research grants from Roche Diagnostics, Siemens Diagnostics, Critical Diagnostics, and BRAHMS. Dr H.K. Gaggin does not have any disclosures.
Identification
Copyright
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
